Paragon 28, Inc. (FNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA.
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA.
| - Industry | - Sector | Mr. Albert DaCosta CEO | NYSE Exchange | 69913P105 CUSIP |
| US Country | 574 Employees | - Last Dividend | - Last Split | 15 Oct 2021 IPO Date |
Paragon 28, Inc., founded in 2010 and based in Englewood, Colorado, is a pioneering company in the development, distribution, and sale of innovative foot and ankle surgical systems both in the United States and internationally. The company has established itself as a leader in the industry by focusing on the creation of specific solutions designed to improve surgical outcomes for patients suffering from foot and ankle conditions. Through its extensive range of products, Paragon 28, Inc. caters to hospitals and ambulatory surgery centers, delivering its services via a comprehensive network of sales representatives and stocking distributors.
Paragon 28, Inc. offers a wide array of products and services designed to meet the diverse needs of foot and ankle surgery, including: